Impact of germline BRCA1/2 mutations on response to neoadjuvant systemic therapy and prognosis in breast cancer: a propensity score matched cohort study.

Breast Cancer Res · 2025 · PMC12096599 · PMID 40405286

Europe PMC DOI

hedged sentence

0.0910

closest p · 1.8× alpha

0.0910

boldest claim

The sentences

did not reach statistical significanceP = 0.091so close (0.05 < p ≤ 0.1)

1 ), the difference in OS between BRCA1/2 PV carriers and noncarriers did not reach statistical significance ( P = 0.091) (Fig. 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.